| BRCA1/2 mutation analysis in 41 ovarian cell lines reveals only one functionally deleterious BRCA1 mutation B Stordal, K Timms, A Farrelly, D Gallagher, S Busschots, M Renaud, ... Molecular oncology 7 (3), 567-579, 2013 | 159 | 2013 |
| BCL-2 system analysis identifies high-risk colorectal cancer patients AU Lindner, M Salvucci, C Morgan, N Monsefi, AJ Resler, M Cremona, ... Gut 66 (12), 2141-2148, 2017 | 53 | 2017 |
| A preclinical evaluation of the PI3K alpha/delta dominant inhibitor BAY 80-6946 in HER2-positive breast cancer models with acquired resistance to the HER2-targeted therapies … N Elster, M Cremona, C Morgan, S Toomey, A Carr, A O’Grady, ... Breast cancer research and treatment 149, 373-383, 2015 | 51 | 2015 |
| Elevated levels of the acute‐phase serum amyloid are associated with heightened lung cancer risk M Cremona, E Calabrò, G Randi, M De Bortoli, P Mondellini, C Verri, ... Cancer: Interdisciplinary International Journal of the American Cancer …, 2010 | 43 | 2010 |
| Bsx, an evolutionary conserved Brain Specific homeoboX gene expressed in the septum, epiphysis, mammillary bodies and arcuate nucleus M Cremona, E Colombo, M Andreazzoli, G Cossu, V Broccoli Gene Expression Patterns 4 (1), 47-51, 2004 | 43 | 2004 |
| Markers of MEK inhibitor resistance in low-grade serous ovarian cancer: EGFR is a potential therapeutic target ML Fernandez, A Dawson, J Hoenisch, H Kim, S Bamford, C Salamanca, ... Cancer cell international 19, 1-17, 2019 | 38 | 2019 |
| Proteomics study of medullary thyroid carcinomas expressing RET germ‐line mutations: Identification of new signaling elements L Gorla, P Mondellini, G Cuccuru, F Micciche, G Cassinelli, M Cremona, ... Molecular Carcinogenesis: Published in cooperation with the University of …, 2009 | 31 | 2009 |
| Targeting the PI3K and MAPK pathways to improve response to HER2-targeted therapies in HER2-positive gastric cancer MJ Mezynski, AM Farrelly, M Cremona, A Carr, C Morgan, J Workman, ... Journal of translational medicine 19 (1), 184, 2021 | 30 | 2021 |
| Combined targeting EGFR and SRC as a potential novel therapeutic approach for the treatment of triple negative breast cancer A Canonici, AL Browne, MFK Ibrahim, KP Fanning, S Roche, NT Conlon, ... Therapeutic advances in medical oncology 12, 1758835919897546, 2020 | 26 | 2020 |
| A preclinical evaluation of the MEK inhibitor refametinib in HER2-positive breast cancer cell lines including those with acquired resistance to trastuzumab or lapatinib J O’Shea, M Cremona, C Morgan, M Milewska, F Holmes, V Espina, ... Oncotarget 8 (49), 85120, 2017 | 26 | 2017 |
| A stepwise integrated approach to personalized risk predictions in stage III colorectal cancer M Salvucci, ML Würstle, C Morgan, S Curry, M Cremona, AU Lindner, ... Clinical Cancer Research 23 (5), 1200-1212, 2017 | 25 | 2017 |
| Preclinical evaluation and reverse phase protein Array-based profiling of PI3K and MEK inhibitors in endometrial carcinoma in vitro O Aslan, M Cremona, C Morgan, LW Cheung, GB Mills, BT Hennessy BMC cancer 18, 1-11, 2018 | 19 | 2018 |
| The impact of ERBB-family germline single nucleotide polymorphisms on survival response to adjuvant trastuzumab treatment in HER2-positive breast cancer S Toomey, SF Madden, SJ Furney, Y Fan, M McCormack, C Stapleton, ... Oncotarget 7 (46), 75518, 2016 | 18 | 2016 |
| Identification and clinical impact of potentially actionable somatic oncogenic mutations in solid tumor samples S Toomey, A Carr, MJ Mezynski, Y Elamin, S Rafee, M Cremona, ... Journal of translational medicine 18, 1-14, 2020 | 16 | 2020 |
| Germline single nucleotide polymorphisms in ERBB3 and BARD1 genes result in a worse relapse free survival response for HER2-positive breast cancer patients … D Cote, A Eustace, S Toomey, M Cremona, M Milewska, S Furney, A Carr, ... PLoS One 13 (8), e0200996, 2018 | 15 | 2018 |
| Frequency, impact and a preclinical study of novel ERBB gene family mutations in HER2-positive breast cancer N Elster, S Toomey, Y Fan, M Cremona, C Morgan, K Weiner Gorzel, ... Therapeutic advances in medical oncology 10, 1758835918778297, 2018 | 14 | 2018 |
| Development of a personalized therapeutic strategy for ERBB-gene-mutated cancers M Milewska, M Cremona, C Morgan, J O’Shea, A Carr, SHK Vellanki, ... Therapeutic Advances in Medical Oncology 10, 1758834017746040, 2018 | 13 | 2018 |
| Proteomic profile in familial breast cancer patients VM Garrisi, S Tommasi, A Facchiano, I Bongarzone, M De Bortoli, ... Clinical Biochemistry 46 (3), 259-265, 2013 | 12 | 2013 |
| Characterization of a serum protein pattern from NSCLC patients treated with Gefitinib VM Garrisi, I Bongarzone, A Mangia, M Cremona, M De Bortoli, E Vaghi, ... Clinical biochemistry 44 (10-11), 936-940, 2011 | 12 | 2011 |
| Stratification of clear cell renal cell carcinoma by signaling pathway analysis M Cremona, V Espina, D Caccia, S Veneroni, M Colecchia, M Pierobon, ... Expert review of proteomics 11 (2), 237-249, 2014 | 11 | 2014 |
